Intrexon Corporation Closes $25 Million Series C Financing

BLACKSBURG, Va., May 14 /PRNewswire/ -- Intrexon Corporation, a privately held life sciences company focused on the development of transcriptional therapeutics for critical human diseases, announced that it has closed a $25 million Series C financing by New River Management V, LP, a private investment fund managed by Third Security, LLC. Previous rounds of investment have been provided by New River Management IV, LP and NewVa Capital Partners, LP, a regional investment partnership. Funds and other entities managed by Third Security have invested a total of $31.5 million in Intrexon to date.

"This investment allows us to increase the pace and depth of our pre- clinical studies in preparation for entering clinical trials, while further expanding our core technology platform," said Robert Beech, chief executive officer of Intrexon. "We are very pleased by this vote of confidence from our investors and look forward with anticipation to the next phase of results from our R&D initiatives."

"This is precisely the type of company we seek to invest in," commented Randal Kirk, founder, chairman and senior managing director of Third Security. "The investment signals our continued belief that Intrexon stands poised to leverage its superior suite of technologies and secure a leading position in the field of cell- and gene-based therapies."

About Intrexon Corporation

Intrexon is a privately held life sciences company headquartered at the Virginia Tech Corporate Research Center in Blacksburg, Virginia, with additional R&D operations in Valley Forge, Pennsylvania. The company is focused on the research and development of transcriptional therapeutics for critical human diseases that have proven intractable for traditional drug modalities, such as metastatic cancer, cardiac failure and progressive neural disorders. Intrexon's transcriptional platform enables unparalleled control and specificity of complex gene programs, including inducible, multigenic programs that modulate specific protein-protein interactions in targeted subcellular locations. More information is available at www.intrexon.com.

About Third Security, LLC

Third Security, LLC is a private equity and venture capital firm formed in 1999 to manage investments in public and private companies. The firm leverages its people, expertise and capital to guide investments and companies to category dominance. More information is available at www.thirdsecurity.com.

About NewVa Capital Partners, LP

NewVa Capital Partners, LP is a private equity/venture capital fund founded in 2004 by Carilion Health System, the Virginia Tech Foundation and Third Security, LLC. The fund is managed by Third Security, LLC and makes early stage investments in companies in the NewVa region of southwestern Virginia. More information is available at www.newvafund.com.

Intrexon Corporation

CONTACT: Shannon Hodous of Intrexon Corporation, +1-540-961-0725,shodous@intrexon.com

>>> Discuss This Story

Back to news